Frontosubthalamic Networks in Parkinson's Disease.

Inclusion criteria

• Participant is willing and able to give informed consent for participation in the study.
• Male or Female, aged 18 years or above.
• Diagnosed with Parkinson's disease who have required implanted STN electrodes for DBS in addition to their dopamine replacement therapy.
• Diagnosed with or without (control group) impulse control disorders since the diagnosis of Parkinson's Disease.
• Participant willing and able to sit in the MEG scanner and follow instructions.
• Participant willing and able to delay their morning dose of dopamine replacement therapy for up to four hours (180 minutes experimental time + journey time).

Exclusion criteria

• Patients with extreme language barrier that cannot understand the purpose or instructions of the study despite the use of an interpreter.
• Other implanted medical devices that may cause artefacts during MEG recordings.
• Participants with a history of co-morbid neurological disorders.
• Participant enrolled onto another clinical trial related to a neurological disorder (including Parkinson's disease) that may interfere with the results of this study.
• Participants who are unable to sit still in a MEG scanner for the duration of this experiment e.g. patients with chronic pain or osteoarthritis. This will be assessed with their primary clinician